注射用重组人白介素-11治疗吉西他滨化疗所致血小板减少的临床观察
|
摘要
目的探讨注射用重组人白介素-11(rh IL-11)治疗吉西他滨化疗所致血小板减少的临床效果。方法选取2014年10月至2016年12月间武汉大学人民医院收治的112例吉西他滨化疗所致血小板减少患者,根据患者意愿(是否同意使用rh IL-11)将其分入观察组和对照组,观察组67例,对照组45例。观察组患者采用rh IL-11治疗,对照组患者采用氨肽素治疗,比较两组患者治疗前及治疗7d后的血小板(PLT)水平、达标例数和达标时间,比较两组患者的临床疗效和不良反应。结果观察组与对照组PLT达标率分别为94.0%和75.6%,达标时间分别为(6.12±1.27)d和(9.65±2.86)d,差异均有统计学意义(均P<0.05);观察组患者总有效率为94.0%,高于对照组患者的75.6%,差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论 rh IL-11治疗吉西他滨化疗所致血小板减少有较好的临床疗效,血小板达标所需时间较短,效率较高,优于一般性升血小板药物。
Objective To explore the clinical efficacy of recombinant human interleukin-11( rh IL-11) for thrombocytopenia induced by gemcitabine chemotherapy. Methods A total of 112 patients with thrombocytopenia induced by gemcitabine chemotherapy were selected at People's Hospital of Wuhan University from October 2014 to December 2016 According to patients' preference,these patients were divided into an observation group( 67 patients) and a control group( 45 patients). Patients in the observation group were given rh IL-11 and patients in the control group were given amino-peptide. Levels of platelet( PLT) level before the treatment and at 7 d after the treatment were compared. Response rate and time as well as clinical efficacy and adverse reactions were also compared. Results Response rate and time was 94. 0% and( 6. 12 ± 1. 27) d for the observation group and 75. 6% and( 9. 65 ± 2. 86) d for the control group,respectively( all P <0. 05). The overall efficacy rate was 94. 0% for the observation group which was higher than 75. 6% of the control group( P < 0. 05). There was no significant difference in the incidence of adverse reactions between the two groups( P > 0. 05). Conclusion rh IL-11 shows good efficacy for thrombocytopenia induced by gemcitabine chemotherapy with short response time and is superior to general platelet drugs.
Objective To explore the clinical efficacy of recombinant human interleukin-11( rh IL-11) for thrombocytopenia induced by gemcitabine chemotherapy. Methods A total of 112 patients with thrombocytopenia induced by gemcitabine chemotherapy were selected at People's Hospital of Wuhan University from October 2014 to December 2016 According to patients' preference,these patients were divided into an observation group( 67 patients) and a control group( 45 patients). Patients in the observation group were given rh IL-11 and patients in the control group were given amino-peptide. Levels of platelet( PLT) level before the treatment and at 7 d after the treatment were compared. Response rate and time as well as clinical efficacy and adverse reactions were also compared. Results Response rate and time was 94. 0% and( 6. 12 ± 1. 27) d for the observation group and 75. 6% and( 9. 65 ± 2. 86) d for the control group,respectively( all P <0. 05). The overall efficacy rate was 94. 0% for the observation group which was higher than 75. 6% of the control group( P < 0. 05). There was no significant difference in the incidence of adverse reactions between the two groups( P > 0. 05). Conclusion rh IL-11 shows good efficacy for thrombocytopenia induced by gemcitabine chemotherapy with short response time and is superior to general platelet drugs.
引文
[1]刘冯,肖丁华,莫东华,等.造血生长因子联合咖啡酸片治疗急性淋巴细胞白血病患者化疗后骨髓抑制[J].华南国防医学杂志,2011,25:313-315.
[2]王凤云,孔凡良,蒋英俊,等.重组人白介素-11应用白血病化疗后血小板减少疗效观察[J].安徽医药,2015,19:1816-1817.
[3]崔洪霞,李玉权,马丽霞,等.吉西他滨联合顺铂与紫杉醇联合顺铂方案一线治疗晚期肺鳞癌临床比较[J].中国老年学杂志,2015,35:5811-5813.
[4]徐雅靖,李晓林,赵谢兰,等.重组人血小板生成素与重组人白介素-11促进白血病患者异基因造血干细胞移植后血小板恢复的疗效比较[J].血栓与止血学,2013,19:145-149.
[5]郭代红,邢午宏,陈超,等.rh TPO等四种升血小板药物临床应用评价及经济学评估[J].中国药物应用与监测,2010,7:5-9.
[6]李兴军,马晓莉,张大伟,等.超大剂量环磷酰胺为主的化疗方案治疗小儿高危神经母细胞瘤的毒副作用及防治[J].中华实用儿科临床杂志,2013,28:141-145.
[7]于丽君,朱国标,李翠莹,等.大量输血患者血小板和出凝血功能变化分析[J].国际检验医学杂志,2013,34:3252-3254.
[8]刘燕,陈方祥,滕方,等.329例大量输血患者成分输血分析[J].重庆医学,2009,38:1433-1433.
[9]赖俊浩,张翀,胡斌,等.大量输血程序对腹部外科创伤性休克患者的应用价值探讨[J].中华普通外科杂志,2014,29:715-718.
[10]于培霞,杨云,王桂琴.重组人源白细胞介素-24联合重组人源核心蛋白聚糖对人类肝细胞癌Hep G2细胞增殖抑制和凋亡诱导协同效应的研究[J].肿瘤研究与临床,2014,26:587-591.
[11]江岷,潘欣,徐晨,等.重组人血小板生成素促进异基因造血干细胞移植血小板恢复的随机对照临床试验[J].血栓与止血学,2011,17:247-253.
[12]余胜珠,杨光华,陈连生,等.注射用重组人白介素-11衍生物治疗恶性肿瘤化疗后血小板减少24例[J].中国药业,2013,22:32-33.
[13]黄辉,章展,李建华,等.重组人白介素-11治疗化疗引起的血小板减少症的临床观察[J].中国药房,2016,27:4998-5000.
[2]王凤云,孔凡良,蒋英俊,等.重组人白介素-11应用白血病化疗后血小板减少疗效观察[J].安徽医药,2015,19:1816-1817.
[3]崔洪霞,李玉权,马丽霞,等.吉西他滨联合顺铂与紫杉醇联合顺铂方案一线治疗晚期肺鳞癌临床比较[J].中国老年学杂志,2015,35:5811-5813.
[4]徐雅靖,李晓林,赵谢兰,等.重组人血小板生成素与重组人白介素-11促进白血病患者异基因造血干细胞移植后血小板恢复的疗效比较[J].血栓与止血学,2013,19:145-149.
[5]郭代红,邢午宏,陈超,等.rh TPO等四种升血小板药物临床应用评价及经济学评估[J].中国药物应用与监测,2010,7:5-9.
[6]李兴军,马晓莉,张大伟,等.超大剂量环磷酰胺为主的化疗方案治疗小儿高危神经母细胞瘤的毒副作用及防治[J].中华实用儿科临床杂志,2013,28:141-145.
[7]于丽君,朱国标,李翠莹,等.大量输血患者血小板和出凝血功能变化分析[J].国际检验医学杂志,2013,34:3252-3254.
[8]刘燕,陈方祥,滕方,等.329例大量输血患者成分输血分析[J].重庆医学,2009,38:1433-1433.
[9]赖俊浩,张翀,胡斌,等.大量输血程序对腹部外科创伤性休克患者的应用价值探讨[J].中华普通外科杂志,2014,29:715-718.
[10]于培霞,杨云,王桂琴.重组人源白细胞介素-24联合重组人源核心蛋白聚糖对人类肝细胞癌Hep G2细胞增殖抑制和凋亡诱导协同效应的研究[J].肿瘤研究与临床,2014,26:587-591.
[11]江岷,潘欣,徐晨,等.重组人血小板生成素促进异基因造血干细胞移植血小板恢复的随机对照临床试验[J].血栓与止血学,2011,17:247-253.
[12]余胜珠,杨光华,陈连生,等.注射用重组人白介素-11衍生物治疗恶性肿瘤化疗后血小板减少24例[J].中国药业,2013,22:32-33.
[13]黄辉,章展,李建华,等.重组人白介素-11治疗化疗引起的血小板减少症的临床观察[J].中国药房,2016,27:4998-5000.